Acumen Pharmaceuticals (ABOS) vs Eledon Pharmaceuticals (ELDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Eledon Pharmaceuticals (ELDN) over the past year, losing 16.7% versus a loss of 38.1%. Over five years, ELDN leads with a -58.1% price change compared with -88.2% for ABOS. Eledon Pharmaceuticals is the larger company by market cap ($173.1 million vs $122.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | ELDN |
|---|---|---|
| Share price | $1.69 | $2.13 |
| Market cap | $122.22M | $173.09M |
| 1-day change | +1.20% | -6.17% |
| YTD return | -19.91% | +41.06% |
| 1-year return | -16.75% | -38.08% |
| 5-year return | -88.25% | -58.07% |
| EPS (TTM) | $-1.64 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-121.33M | $-45.62M |
| 52-week high | $3.60 | $4.60 |
| 52-week low | $1.50 | $1.35 |
| Distance from 52-week high | -53.06% | -53.70% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +349.70% | +322.54% |
| Average volume | 439.26K | 914.37K |
| Shares outstanding | 72.32M | 81.26M |
| Employees | 60 | 33 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed ELDN by 21.3 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Healthcare · Biotechnology · 33 employees
ABOS vs ELDN FAQ
Which is bigger, Acumen Pharmaceuticals or Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $173.09M compared with $122.22M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or ELDN?
ABOS returned -16.75% over the past 12 months, compared with -38.08% for ELDN (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Eledon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.